Concurrent atezolizumab was linked to HSV-1 toxicity during adaptive head and neck radiotherapy
Radiation reached 60 Gy in 15 fractions with adjuvant atezolizumab, while concurrent dosing was followed by HSV-1 reactivation in three of five patients.
Latest research
Search the archiveEQD2 remains essential but uncertain in modern cervical HDR brachytherapy
EQD2 should remain the reporting standard, but delivery time, dose gradients, biological assumptions and dose accumulation materially affect its interpretation.
Durvalumab with radiotherapy achieved 39% two-year PFS in cCRT-ineligible NSCLC
Concurrent and consolidative durvalumab with definitive radiotherapy produced 39% two-year progression-free survival in patients ineligible for concurrent chemoradiotherapy.
One RapidPlan model generated ocular stereotactic plans across three fractionation schedules
A single knowledge-based model generated comparable ocular plans for 25 Gy once, 42 Gy in three fractions and 50 Gy in five.
Three MRI radiotherapy guidelines were largely consistent but differed in scope
IPEM, AAPM and NCS recommendations largely aligned, with complementary guidance for MRI simulation, MR-only workflows and MR-Linac quality assurance.
Daily adaptation improved target coverage and rectal sparing in postoperative prostate radiotherapy
Daily adaptation increased prostate-bed coverage from 92.1% to 98.5% and reduced high-dose rectal exposure during hypofractionated salvage radiotherapy.
Review maps three strategies to reduce toxicity in nasopharyngeal carcinoma
Response-guided target reduction has the strongest evidence, while proton therapy and immunotherapy-based de-escalation remain less established.
HyperSight protocol selection substantially changed CBCT organ dose
Low Dose HyperSight protocols reduced exposure by 55%, while Slow and Large protocols increased imaging dose and accentuated secondary-risk estimates.
FLASH reduced corneal injury after whole-brain irradiation in mice
FLASH preserved corneal thickness and collagen organization better than conventional irradiation at 10 and 15 Gy, but protection weakened at 20 Gy.
Skin microbiome signatures were associated with moderate-to-severe breast radiodermatitis
Clostridium, Anaerococcus US436 and Granulicatella elegans were associated with moderate-to-severe acute dermatitis during breast radiotherapy.
Five-fraction prostate radiotherapy reduced estimated carbon emissions by 59%
Five-fraction prostate radiotherapy produced 58.6% lower estimated carbon emissions than a 26-fraction schedule, mainly by reducing patient travel.
Review maps three strategies to reduce toxicity in nasopharyngeal carcinoma
Response-guided target reduction and sequential chemoradiotherapy have the strongest evidence, while proton and immunotherapy-based approaches remain less established.
Five-fraction whole-breast irradiation showed low short-term toxicity across 28 Italian centres
Whole-breast irradiation with 26 Gy in five fractions produced mainly grade 1 toxicity in 2,036 patients, including those receiving a boost.
Two-fraction HDR brachytherapy achieved durable control in favourable-risk prostate cancer
High-dose-rate brachytherapy using 13.5 Gy twice achieved 81.6% ten-year biochemical control with limited late genitourinary toxicity.
Small gastrointestinal PRV margins limited dose increases but did not encompass pancreatic SABR motion
Two- to five-millimetre gastrointestinal margins usually limited delivered dose increases but frequently failed to encompass interfraction organ motion.